Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abvc Biopharma (ABVC) Debt to Equity (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Debt to Equity for 10 consecutive years, with $0.07 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity fell 90.08% year-over-year to $0.07, compared with a TTM value of $0.07 through Dec 2025, down 90.08%, and an annual FY2025 reading of $0.07, down 90.08% over the prior year.
  • Debt to Equity was $0.07 for Q4 2025 at Abvc Biopharma, up from $0.07 in the prior quarter.
  • Across five years, Debt to Equity topped out at $3.63 in Q2 2021 and bottomed at $0.05 in Q2 2022.
  • Average Debt to Equity over 5 years is $0.48, with a median of $0.11 recorded in 2021.
  • The sharpest move saw Debt to Equity skyrocketed 648.25% in 2021, then crashed 98.62% in 2022.
  • Year by year, Debt to Equity stood at $0.12 in 2021, then surged by 397.48% to $0.59 in 2022, then grew by 22.59% to $0.72 in 2023, then dropped by 4.48% to $0.69 in 2024, then crashed by 90.08% to $0.07 in 2025.
  • Business Quant data shows Debt to Equity for ABVC at $0.07 in Q4 2025, $0.07 in Q3 2025, and $0.09 in Q2 2025.